公开(公告)号：EP1612208B1

公开(公告)日：2011-08-31

申请号：EP05109059.5

申请日：2002-03-11

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Naganawa, Atsushi ,  Saitoh, Tetsuji ,  Kobayashi, Kaoru ,  Maruyama, Takayuki ,  Nakai, Yoshihiko ,  Hashimoto, Shinsuke

IPC分类号： C07D307/64 ,  C07D277/36 ,  C07D213/71 ,  C07D405/12 ,  C07D417/12 ,  C07D401/12 ,  C07D413/12 ,  A61K31/341 ,  A61K31/426 ,  A61K31/4402 ,  A61K31/4406 ,  C07D213/70 ,  A61P13/02

CPC分类号： C07D213/70 ,  C07D277/36 ,  C07D307/64 ,  C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12

公开(公告)号：EP1685832B1

公开(公告)日：2011-04-06

申请号：EP04792173.9

申请日：2004-10-01

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： TATEISHI, Narito ,  YAMAMOTO, Junki, Ono Pharmaceutical Co., Ltd. ,  KAWAHARADA, Soichi, Ono Pharmaceutical Co., Ltd. ,  AKIYAMA, Tsutomu, Ono Pharmaceutical Co., Ltd. ,  HOSHIKAWA, Masamitsu, Ono Pharmaceutical Co., Ltd.

IPC分类号： A61K31/19 ,  A61K31/20 ,  A61P9/00 ,  A61P25/00 ,  A61P25/02 ,  A61P25/14 ,  A61P25/16 ,  A61P25/28 ,  A61P35/00

CPC分类号： A61K31/20 ,  A61K31/19 ,  A61K45/06

摘要： Nerve regeneration promoters containing compounds represented by the following general formula (1), salts thereof or prodrugs of the same: (1) wherein each symbol is as defined in the specification. The compounds represented by the general formula (1) inhibit nerve cell death and promote the formation of new nerve cells and nerve cell regeneration and also promote the repair and regeneration of nerve tissues and functions through neurite extension, because of serving as a stem cell (nerve stem cell, embryonic stem cell, bone marrow cell, etc.) proliferation/differentiation promoter, a nerve cell precursor proliferation/differentiation promoter, a neurotrophic factor activity enhancer, a neurotrophic factor-like substance or a neurodegeneration inhibitor. Furthermore, these compounds are useful in preparing cells for transplantation (nerve stem cells, nerve cell precursors, nerve cells, etc.) from a brain tissue, bone marrow, embryonic stem cells, etc. At the same time, these compounds promote the take, proliferation, differentiation and function expression of transplanted cells, which makes them useful as preventives and/or remedies for neurodegenerative diseases.

公开(公告)号：EP2270051A2

公开(公告)日：2011-01-05

申请号：EP10176748.1

申请日：2004-01-22

申请人： Ono Pharmaceutical Co., Ltd. ,  Honjo, M r. Tasuku

发明人： Honjo, Tasuku ,  Shibayama, Shiro ,  Takeda, Kazuhiko ,  Matsuo, Masayoshi ,  Yoshida, Takao ,  Miyamoto, Masakazu

IPC分类号： C07K16/28 ,  C07K16/46

CPC分类号： C07K16/2818 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/2803 ,  C07K16/2809 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/73

摘要： The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.

摘要翻译： 本发明涉及对人PD-1特异性的物质，其包含识别人PD-1的部分，识别人PD-1表达细胞的细胞膜中的膜蛋白的部分和接头。 由于对人PD-1特异性的物质可以选择性地识别人PD-1和人PD-1表达细胞的细胞膜上的膜蛋白，并且可以传递人PD-1的抑制信号，因此它可用于治疗和/或 预防免疫病引起的疾病。

公开(公告)号：EP1619498B1

公开(公告)日：2011-01-05

申请号：EP04727715.7

申请日：2004-04-15

申请人： ONO PHARMACEUTICAL CO., LTD. ,  Honjo, Tasuku

发明人： HONJO, Tasuku ,  OKAZAKI, Taku

IPC分类号： G01N33/50 ,  G01N33/15 ,  G01N33/53 ,  C12Q1/02 ,  A61K45/00 ,  A61K38/17 ,  A61P9/00 ,  G01N33/564

CPC分类号： G01N33/564 ,  A61K38/17 ,  G01N33/5061 ,  G01N2800/325

摘要： A method of screening a substance inhibiting the onset of a disease in which an anti-myocardial troponin I autoantibody participates; a medicinal composition for treating a heart disease and a base material for treating a heart disease containing a substance produced by the above method; an apparatus for treating a heart disease in which an anti-myocardial troponin I autoantibody participates whereby the above antibody is removed; a method of constructing an animal for evaluating a heart disease which comprises administering an anti-myocardial troponin I autoantibody; a method of selecting a remedy for a heart disease with the use of the above animal; and a method of diagnosing dilated cardiomyopathy which comprises quantifying an anti-myocardial troponin I autoantibody. The above-described treatment apparatus whereby the anti-myocardial troponin I autoantibody is removed and the medicinal composition for treating a disease in which the antibody participate are useful in treating and/or preventing a heart disease.

公开(公告)号：EP2206517A1

公开(公告)日：2010-07-14

申请号：EP10161767.8

申请日：2003-07-02

申请人： Ono Pharmaceutical Co., Ltd. ,  Honjo, Tasuku

发明人： Honjo, Tasuku ,  Minato, Nagahiro ,  Iwai, Yoshiko ,  Shibayama, Shiro

IPC分类号： A61K45/00 ,  A61K38/17 ,  A61K39/395 ,  A61K31/7088 ,  A61P31/00 ,  A61P35/00 ,  A61P35/04 ,  A61P37/04 ,  C12N5/10 ,  C12Q1/02 ,  G01N33/50 ,  A61K35/14 ,  A61K33/00 ,  A61K35/00 ,  G01N33/574 ,  A01K67/027 ,  A61K31/00 ,  C07K16/28 ,  C07K14/705 ,  C07K16/46

CPC分类号： C07K16/2818 ,  A61K9/0019 ,  A61K31/7088 ,  A61K38/1774 ,  A61K38/212 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/02 ,  A61K47/26 ,  A61K2039/505 ,  A61K2039/507 ,  C07K14/70521 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/30 ,  C12Q1/025 ,  G01N33/5011 ,  G01N33/574 ,  G01N2500/00 ,  Y02A50/39 ,  Y02A50/394 ,  Y02A50/463 ,  Y02A50/466

摘要： Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods.
The compositions of the present invention that inhibits the function of PD-1,PD-L1, or PD-L2 are useful for cancer or infection treatment.
The compositions of the present invention comprise an anti-PD-L1 antibody.

摘要翻译： 通过由PD-1，PD-L1或PD-L2诱导的免疫抑制信号的抑制和使用它们的疗法，包括作为活性成分的免疫增强底物，通过免疫增强引起的癌症或感染治疗的组合物，用于癌症或感染的底物的筛选方法 治疗，用于筛选方法的细胞系，选择用于癌症治疗的底物的评价方法，以及用于评价方法的癌细胞移植的哺乳动物。 抑制PD-1，PD-L1或PD-L2的功能的本发明的组合物可用于癌症或感染治疗。 本发明的组合物包含抗PD-L1抗体。

公开(公告)号：EP2172222A3

公开(公告)日：2010-06-23

申请号：EP10150486.8

申请日：2005-04-25

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Nakade, Shinji ,  Shouno, Tomoyuki ,  Shimizu, Takao ,  Yokomizo, Takehiko ,  Iizuka, Yoshiko

IPC分类号： A61K45/00 ,  A61K31/192 ,  A61K31/4402 ,  A61P1/16 ,  A61P9/10 ,  A61P17/02 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/00 ,  A61P43/00

CPC分类号： C07D213/38 ,  A61K31/192 ,  A61K31/4402 ,  C07C229/38 ,  C07C233/47 ,  C07C233/51 ,  C07C233/63 ,  C07C233/87 ,  C07C235/52 ,  C07C255/58 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2601/16 ,  C07C2602/42

摘要： [PROBLEM] The compound that selectively binds to BLT2 and the preventive and/or therapeutic drug for BLT2-mediated disease such as skin disease are needed.
[MEANS] FOR SOLVING THE PROBLEMS] The present invention provides the compound with BLT2 binding activity, salt thereof, solvate thereof or prodrug thereof. Since the compound with BLT2 binding activity, particularly the compound represented by the formula (I)

, salt thereof, solvate thereof or prodrug thereof (symbols in formula have the same meanings as specification.) have BLT2 binding activity, it is useful for prevention and/or therapy of BLT2 mediated diseases, e.g., dermatosis, intestinal disease, HIV infection, acquired immunodeficiency syndrome, rejection to transplant, transplant rejection, graft-versus-host disease, autoimmune disease, allergic disease, inflammation, infection, ulcers, lymphoma, malignant tumor, leucaemia, arterial sclerosis, hepatitis, hepatic cirrhosis or cancer, etc.

摘要翻译： [问题]需要选择性结合BLT2的化合物和用于BLT2介导的疾病如皮肤病的预防和/或治疗药物。 解决问题的手段本发明提供具有BLT2结合活性的化合物，其盐，其溶剂合物或其前药。 由于具有BLT2结合活性的化合物，特别是由式（I）表示的化合物，其盐，其溶剂合物或其前药（式中的符号与说明书同义）具有BLT2结合活性，因此可用于预防和 /或BLT2介导的疾病的治疗，例如皮肤病，肠道疾病，HIV感染，获得性免疫缺陷综合征，移植排斥反应，移植排斥反应，移植物抗宿主病，自身免疫性疾病，过敏性疾病，炎症，感染，溃疡，淋巴瘤， 恶性肿瘤，白血病，动脉硬化，肝炎，肝硬化或癌症等。

公开(公告)号：EP2177513A1

公开(公告)日：2010-04-21

申请号：EP08827402.2

申请日：2008-08-11

申请人： ONO Pharmaceutical Co., Ltd.

发明人： NAGANAWA, Atsushi ,  NAGASE, Toshihiko

IPC分类号： C07D265/36 ,  A61K31/538 ,  A61K45/00 ,  A61P1/04 ,  A61P1/16 ,  A61P7/02 ,  A61P9/00 ,  A61P9/10 ,  A61P11/00 ,  A61P11/02 ,  A61P11/06 ,  A61P17/00 ,  A61P17/04 ,  A61P17/10 ,  A61P19/02 ,  A61P21/00 ,  A61P21/04 ,  A61P25/00 ,  A61P25/06 ,  A61P25/20 ,  A61P27/02

CPC分类号： C07D265/36 ,  A61K31/00 ,  A61K31/538 ,  A61K45/06 ,  A61K2300/00

摘要： A compound represented by formula (I),

wherein
R 1 represents a hydrogen atom, etc.,
R 2 and R 3 each independently represents a hydrogen atom, optionally oxidized C1-4 alkyl group or optionally protected hydroxyl group, or R 2 and R 3 taken together represent optionally oxidized C2-5 alkylene group,
R 4 represents an optionally oxidized C1-6 alkyl group, etc.,
R 5 represents an optionally oxidized C1-6 alkyl group, etc.,
R 6 represents an optionally oxidized C1-6 alkyl group, etc.,
m represents 0 or an integer from 1 to 3,
n represents 0 or an integer from 1 to 4, and
i represents 0 or an integer from 1 to 7.

摘要翻译： 由式（I）表示的化合物，其中R 1表示氢原子等，R 2和R 3各自独立地表示氢原子，任选氧化的C 1-4烷基或任选被保护的羟基，或者R 2和R 3一起表示任选地 氧化的C 2-5亚烷基，R 4表示任选氧化的C 1-6烷基等，R 5表示任选氧化的C 1-6烷基等，R 6表示任选氧化的C 1-6烷基等，m 表示0或1至3的整数，n表示0或1至4的整数，且i表示0或1至7的整数。

公开(公告)号：EP1650182B1

公开(公告)日：2009-10-07

申请号：EP04747782.3

申请日：2004-07-14

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： IMAWAKA, Haruo c/o Ono Pharmaceutical Co., Ltd. ,  HASEGAWA, Tomoyuki c/o Ono Pharm. Co., Ltd. ,  SAKUYAMA, Shigeru c/o Ono Pharm. Co., Ltd. ,  KAWANAKA, Yasufumi c/o Ono Pharm. Co., Ltd. ,  AKIYAMA, Tsutomu c/o Ono Pharmaceutical Co., Ltd. ,  HOSHIKAWA, Masamitsu c/o Ono Pharm. Co., Ltd. ,  MATSUDA, Saiko c/o Ono Pharmaceutical Co., Ltd.

IPC分类号： C07C55/02 ,  C07C59/01 ,  C07C59/185 ,  A61K31/19 ,  A61K31/194 ,  A61K31/366 ,  A61K45/00 ,  A61P25/00 ,  A61P25/14 ,  A61P25/16 ,  A61P25/28

CPC分类号： C07C59/185 ,  C07C59/01

摘要： A compound represented by the general formula (I): (wherein R represents optionally protected hydroxy or oxo; indicates alpha configuration, beta configuration, or a mixture of these in an arbitrary proportion; n is an integer of 1 to 3; and m is an integer of 0 to 10, provided that two or more R 's are not bonded to the same carbon atom other than the terminal carbon atoms), a salt of the compound, or a prodrug of either. The compound represented by the general formula (I) is effective in, e.g., improving the function of astrocytes. It is useful as a preventive and/or therapeutic agent for brain infarction or nerve function disorders after brain infarction and for neurodegenerative diseases such as Parkinson's disease, Parkinson's syndrome, amyotrophic lateral sclerosis, and Alzheimer's disease.

公开(公告)号：EP1974727A1

公开(公告)日：2008-10-01

申请号：EP06842989.3

申请日：2006-12-21

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： KAJITANI, Hitoshi ,  FUNAKOSHI, Yosuke ,  KITAO, Dai

IPC分类号： A61K31/20 ,  A61P9/10 ,  A61P25/28

CPC分类号： A61K31/20

摘要： An agent for treating acute cerebral infarction, comprising (2R)-2-propyloctanoic acid or a salt thereof, which is used for administration after a lapse of time of from about 5 hours to about 72 hours from the onset of the disease is useful for treating acute cerebral infarction, since it safely improves acute cerebral infarction or accompanying symptoms in the patient of acute cerebral infarction, specifically in the patient of acute cerebral infarction defined as a score of 7 to 22 on NIH Stroke Scale.

摘要翻译： 用于治疗急性脑梗死的药物，其包含（2R）-2-丙基辛酸或其盐，其用于在疾病发作后约5小时至约72小时经过时间后施用用于 治疗急性脑梗死，因为它安全地改善急性脑梗死患者的急性脑梗死或伴随症状，特别是在急性脑梗死患者中，NIH中风量表的得分为7至22。

公开(公告)号：EP1961744A1

公开(公告)日：2008-08-27

申请号：EP06832893.9

申请日：2006-11-17

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： KOKUBO, Masaya ,  OCHIAI, Hiroshi ,  TAKAOKA, Yoshikazu ,  SHIBAYAMA, Shiro

IPC分类号： C07D233/64 ,  A61K31/417 ,  A61K31/4178 ,  A61K31/438 ,  A61K31/454 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/55

CPC分类号： C07D403/12 ,  C07D233/64 ,  C07D401/12 ,  C07D403/14 ,  C07D471/10 ,  C07D498/10

摘要： A compound represented by general formula (I):

a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic erythematosus, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiac /vascular disease(for example, arteriosclerosis, myocardial infarction, stenocardia, cerebral infarction, chronic arterial occlusive disease, etc.), metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), a preventive and/or therapeutic agent for cancerous diseases or infections, or an agent for regeneration therapy.

摘要翻译： 由通式（I）表示的化合物：其盐，其溶剂合物或其前药，其中所有符号如本说明书中所定义，具有对CXCR4的拮抗活性，因此可用作预防和/或治疗剂 CXCR4介导的疾病，例如炎症和免疫疾病（例如类风湿性关节炎，关节炎，全身性红斑狼疮，视网膜病变，黄斑变性，肺纤维化，移植器官排斥反应等），过敏性疾病，感染（例如人类免疫缺陷 病毒感染，获得性免疫缺陷综合征等），精神神经病，脑疾病，心脏/血管疾病（例如动脉硬化，心肌梗死，心动过速，脑梗死，慢性动脉闭塞性疾病等），代谢疾病和癌性疾病 （例如癌症，癌症转移等），癌性疾病或感染的预防和/或治疗剂， 或再生治疗剂。